This is the statement of the motions.. (If you need more detail you will have to go to the PaceMonitor web site. They have a 14 day trial.)
1.)THE AMENDED COMPLAINT SHOULD BE DISMISSED PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 12(b)(6) BECAUSE PLAINTIFFS FAIL TO PLEAD ANY COGNIZABLE CLAIM AGAINST DR. OTIKO AND VIADERMA. ----------------------------------------------------------------
1.) THE COURT SHOULD DECLINE TO EXERCISE PERSONAL JURISDICTION OVER VIADERMA AND DR. OTIKO AS PERSONAL JURISDICTION IN SOUTH DAKOTA IS INCONSISTENT WITH THE CONSTITUTIONAL GUARANTEES OF DUE PROCESS.
2.) THE COURT SHOULD FIND VENUE IN SOUTH DAKOTA IS IMPROPER AND TRANSFER THE CASE TO THE CENTRAL DISTRICT OF CALIFORNIA.
Shareholder Update & Current Share Structure: ViaDerma, Inc., has total Authorized 400,000,000 shares, the issued and outstanding is 380,214,603 shares of Common Stock.
To date the Insiders in the Company have not sold any stock.
Dr._Christopher_Otiko, DPM IS A HIGHLY RESPECTED DOCTOR IN THE INDUSTRY ***SEE_BELOW
Dr. Otiko is one of the finest, most knowledgable doctors I have had the pleasure of working with. Because I have homes in 2 states (UT (resident) and CA (non-resident)) I have to have doctors in both states. I have some of the finest physicians on this planet. Chris definitely ranks right up there. His "bedside matter" is one of the best also. He takes time to explain issues to his patients. I have an insurance background (former senior executive officer for 2 Fortune 200 Insurance Hilding Companies) and Chris is honorable too. Plus his treatments were adn are successful for me. I strongly recommend him to anyone who needs his services. Was this rating useful? flag | Submitted January 21, 2013
Dr. Christopher Otiko, DPM - Moreno Valley, CA - Podiatry ... www.healthgrades.com/provider/christopher-otiko-3bfld
4.8/5 · 39 ratings Visit Healthgrades for information on Dr. Christopher Otiko, DPM Find Phone & Address information, medical practice history, affiliated hospitals and more. Dr. Christopher A. Otiko - Reseda, CA - Podiatrist Reviews ... www.ratemds.com › Doctors › California › Reseda › Podiatrists
4.9/5 · 37 ratings · Reseda, California Dr. Christopher A. Otiko has a 4.9/5 rating from patients. Visit RateMDs for Dr. Christopher A. Otiko reviews, contact info, practice history, affiliated hospitals ...
Chris Otiko - 12 Reviews - Podiatrists - 6650 Reseda Blvd ... m.yelp.com › Health & Medical › Doctors › Podiatrists
4.5/5 · 12 reviews · Reseda, CA · (818) 708-7668 12 reviews of Chris Otiko "Thank you Dr. Otiko for helping me with my concern for my left foot! You are very knowledgeable and your staff was very friendly! I'm glad ...
Chris Otiko in Reseda | Chris Otiko 6650 Reseda Blvd, Ste ... local.yahoo.com › … › Doctors & Clinics › Podiatry 4.5/5 · 12 reviews · Podiatry · 6650 Reseda Blvd, Ste 101a · (818) 708-7668 Find Chris Otiko in ... love the front desk ladies! they are all so nice and very helpful. they speak a couple of languages which is a plus. Dr. Otiko himself is ... Chris Otiko - Last Updated 15 June 2017 - 12 Reviews ... www.yelp.com.au › Health & Medical › Doctors › Podiatrists
4.5/5 · 12 Yelp reviews · Reseda, CA · +1-818-708-7668 12 reviews of Chris Otiko "Thank you Dr. Otiko for helping me with my concern for my left foot! You are very knowledgeable and your staff was very friendly! I'm glad ...
Contact and Location Phone (818) 708-7668 Fax (310) 943-1457 Address 6650 Reseda Blvd Suite 101a Reseda, California 91335 Dr. Christopher Otiko is one of 6 Reseda Podiatrists. He has been practicing for 20 years and specializes primarily in Podiatry, practicing in Reseda, California.
NPI Number 1912335381 Similar Providers Entity Type Code Organization Provider Name / Organization CHRISTOPHER OTIKO Provider Business Mailing Address
First Line 16122 COVELLO ST Second Line
City VAN NUYS State CA Postal Code (Zip) 91406-2910 Country US Phone 818-789-8593 Fax Provider Business Practice Location
First Line 16122 COVELLO ST Second Line
City VAN NUYS State CA Postal Code (Zip) 91406-2910 Country US Phone 818-789-8593 Fax
Authorized Official
Title or Position CEO Name CHRISTOPHER OTIKO Credential DPM Telephone Number 818-836-2475 Provider Enumeration Date 10/23/2013 Last Updated 10/23/2013
Detailed Information
NPI Number 1912335381 has the "Organization" type of ownership and has been registered to the following primary business legal name (which is a provider name or healthcare organization name) — CHRISTOPHER OTIKO . Records indicate that the provider gender is "". The enumeration date of this NPI Number is 10/23/2013. NPI Number information was last updated on 10/23/2013. The provider is physically located (Business Practice Location) at: 16122 COVELLO ST VAN NUYS, CA 91406-2910, US CHRISTOPHER OTIKO can be reached at his practice location using the following numbers: Phone: 818-789-8593 Fax: The provider's official mailing address is: 16122 COVELLO ST VAN NUYS, CA 91406-2910, US
The contact numbers associated with the mailing address are: Phone: 818-789-8593 Fax: The authorized official registered with the "1972504793" NPI Number is CHRISTOPHER CHRISTOPHER. The authorized official title (position) is CEO. You can reach the authorized official at the following phone number 818-836-2475. Scope of Practice
The following information about the specialty of the provider is available: # Taxonomy Code Taxonomy Specialty License Number License State 1 213ES0103X Foot & Ankle Surgery E4159 CA
Legacy (other) Identifiers For crosswalk purposes, the following legacy (non-NPI) identifiers are available for this provider: # Provider Identifier Identifier Type Identifier State Issuer 1 U71705 MEDICARE UPIN CA
Reference NPI Information
Full replica of the CMS (NPPES) NPI record: Field Name Value Description NPI 1912335381 10-position all-numeric identification number assigned by the NPS to uniquely identify a health care provider. Entity Type Organization Code describing the type of health care provider that is being assigned an NPI. Codes are: 1 = (Person): individual human being who furnishes health care; 2 = (Non-person): entity other than an individual human being that furnishes health care (for example, hospital, SNF, hospital subunit, pharmacy, or HMO). Is Organization Subpart N The "Is the organization a subpart?" question must be answered. If the organization is a subpart, the Parent Organization Legal Business Name (LBN) and Parent Organization Taxpayer Identification Number (TIN) fields must be completed. The Parent Organization LBN and TIN fields can only be completed if the answer to the subpart question is Yes. Many organization health care providers who apply for NPIs are not legal entities themselves but are parts of other organization health care providers that are legal entities (the "parents"). Here are three examples of organization health care providers that may be considered subparts and may apply for NPIs if so directed by their "parents": (1) The psychiatric unit in a hospital is not a legal entity but is part of the hospital (the "parent"), which is a legal entity. The legal entity must obtain an NPI. The psychiatric unit is an example of a subpart that could have its own NPI if the hospital determines that it should. (2) A group practice that is not a sole proprietorship has a main location and could have other offices in different locations, but each office is not a separate legal entity; instead, each office is part of the corporation (the "parent") which is a legal entity. The offices are examples of subparts that could have their own NPIs if the main location determines that they should. (3) A pharmacy fills prescriptions for patients whose physicians have prescribed medications for them and may also rent or sell durable medical equipment to patients whose physicians have ordered such equipment for them. Neither the pharmacy line of business nor the DME line of business represent legal entities; instead, both lines of business are part of an organization (the "parent") that is a legal entity. Each line of business represents a different Healthcare Provider Taxonomy or area of specialization that often submits its own electronic claims to health plans. The "parent"-we don't know who the parent is in this example-must ensure that each subpart that submits its own claims to health plans has its own NPI. Provider Organization Name (Legal Business Name) CHRISTOPHER OTIKO Provide organization name (legal business name used to file tax returns with the IRS). The Organization Name field allows the following special characters: ampersand, apostrophe, "at" sign, colon, comma, forward slash, hyphen, left and right parentheses, period, pound sign, quotation mark, and semi-colon. A field cannot contain all special characters. Provider Other Organization Name VALLEY OAKS PODIATRY & WOUND CARE GROUP Other name by which the organization provider is or has been known. Provider Other Organization Name Type Code 3 Code identifying the type of other name. Codes are: 1 = former name; 2 = professional name; 3 = doing business as (d/b/a) name; 4 = former legal business name; 5 = other. Provider First Line Business Mailing Address 16122 COVELLO ST The first line mailing address of the provider being identified. This data element may contain the same information as ''Provider first line location address''. Provider Business Mailing Address City Name VAN NUYS The City name in the mailing address of the provider being identified. This data element may contain the same information as ''Provider location address City name''. Provider Business Mailing Address State Name CA The State or Province name in the mailing address of the provider being identified. This data element may contain the same information as ''Provider location address State name''. Provider Business Mailing Address Postal Code 91406-2910 The postal ZIP or zone code in the mailing address of the provider being identified. NOTE: ZIP code plus 4-digit extension, if available. This data element may contain the same information as ''Provider location address postal code''. Provider Business Mailing Address Country Code US The country code in the mailing address of the provider being identified. This data element may contain the same information as ''Provider location address country code''. Provider Business Mailing Address Telephone Number 818-789-8593 The telephone number associated with mailing address of the provider being identified. This data element may contain the same information as ''Provider location address telephone number''. Provider First Line Business Practice Location Address 16122 COVELLO ST The first line location address of the provider being identified. For providers with more than one physical location, this is the primary location. This address cannot include a Post Office box. Provider Business Practice Location Address City Name VAN NUYS The city name in the location address of the provider being identified. Provider Business Practice Location Address State Name CA The State or Province name in the location address of the provider being identified. Provider Business Practice Location Address Postal Code 91406-2910 The postal ZIP or zone code in the location address of the provider being identified. NOTE: ZIP code plus 4-digit extension, if available. Provider Business Practice Location Address Country Code US The country code in the location address of the provider being identified. Provider Business Practice Location Address Telephone Number 818-789-8593 The telephone number associated with the location address of the provider being identified. Provider Enumeration Date 10/23/2013 The date the provider was assigned a unique identifier (assigned an NPI). Last Update Date 10/23/2013 The date that a record was last updated or changed. Authorized Official Last Name OTIKO The last name of the person authorized to submit the NPI application or to change NPS data for a health care provider. Authorized Official First Name CHRISTOPHER The first name of the authorized official Authorized Official Title or Position CEO The title or position of the authorized official Authorized Official Name Prefix Text DR. Authorized Official Name Prefix Text Authorized Official Credential Text DPM Authorized Official Credential Text Authorized Official Telephone Number 818-836-2475 The 10-position telephone number of the authorized official. Healthcare Provider Taxonomy Code #1 213ES0103X The Health Care Provider Taxonomy code is a unique alphanumeric code, ten characters in length. The code set is structured into three distinct "Levels" including Provider Type, Classification, and Area of Specialization. Healthcare Provider Taxonomy 1 Foot & Ankle Surgery Healthcare Provider Taxonomy #1 Provider License Number 1 E4159 Certain taxonomy selections will require you to enter your license number and the state where the license was issued. Select Foreign Country in the state drop down box if the license was issued outside of United States. The License Number field allows the following special characters: ampersand, apostrophe, colon, comma, forward slash, hyphen, left and right parentheses, period, pound sign, quotation mark, and semi-colon. A field cannot contain all special characters. DO NOT report the Social Security Number (SSN), IRS Individual Taxpayer Identification Number (ITIN) in this section. Provider License Number State Code 1 CA Provider License Number State Code #1 Healthcare Provider Primary Taxonomy Switch 1 Y Primary Taxonomy: X - The primary taxonomy switch is Not Answered; Y - The taxonomy is the primary taxonomy (there can be only one per NPI record); N - The taxonomy is not the primary taxonomy. Other Provider Identifier 1 U71705 Other Provider Identifier #1 Other Provider Identifier Type 1 MEDICARE UPIN Other Provider Identifier Type #1 Other Provider Identifier State 1 CA Other Provider Identifier State #1 Healthcare Provider Taxonomy Group 1 193400000X SINGLE SPECIALTY GROUP Healthcare Provider Taxonomy Group 1 Healthcare Provider Taxonomy Group Description 1 Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization.
Right Now, A Dismissal is not priced in at all! The Current Share Price Definitely Reflects The Uncertainty Caused By The Lawsuit and Everyone is expecting it to go to some type of arbitration and settlement vs a drawn out TRIAL.
I personally think a dismissal is possible and right now in favor of Viaderma. A Dismissal will cause an immediate surge in the share price in my opinion as nobody had expected one to happen this quickly, if at all.
Friday, July 07, 2017 48 misc Joinder Fri 3:55 PM JOINDER by Defendants Howard Phillips, LLC, D. Howard Phillips, Phillips Company re39 MOTION to Dismiss ,40 Memorandum in Support of Motion (Tschetter, Paul)
47 notice Notice of Appearance Fri 3:53 PM NOTICE of Appearance by Meghann M. Joyce on behalf of Howard Phillips, LLC, D. Howard Phillips, Phillips Company. (Joyce, Meghann)
46 misc Affidavit Fri 2:38 PM AFFIDAVIT of D. Howard Phillips re45 Memorandum in Support of Motion,44 MOTION to Dismiss for Lack of Jurisdiction and Improper Venue
Tuesday, June 20, 2017 43 respm Affidavit in Support of Motion Tue 4:14 PM AFFIDAVIT in Support re41 MOTION to Dismiss for Lack of Jurisdiction and Improper Venue Affidavit of Dr. Christopher Otiko filed by Christopher Ayo Otiko, ViaDerma, LLC. (Wilka, Thomas)
42 respm Memorandum in Support of Motion Tue 4:10 PM MEMORANDUM in Support re41 MOTION to Dismiss for Lack of Jurisdiction and Improper Venue filed by Christopher Ayo Otiko, ViaDerma, LLC. (Wilka, Thomas)
41 motion Dismiss/Lack of Jurisdiction Tue 4:09 PM MOTION to Dismiss for Lack of Jurisdiction and Improper Venue by Christopher Ayo Otiko, ViaDerma, LLC. (Wilka, Thomas)
40 respm Memorandum in Support of Motion Tue 4:05 PM MEMORANDUM in Support re39 MOTION to Dismiss filed by Christopher Ayo Otiko, ViaDerma, LLC. (Wilka, Thomas)
39 motion Dismiss Tue 4:03 PM MOTION to Dismiss by Christopher Ayo Otiko, ViaDerma, LLC. (Wilka, Thomas) Tuesday, June 06, 2017
The problem Steven Keogh has, is the fact that he has done nothing to "Revive" the abandoned patent in a reasonable time and failed to respond to the US PATENT TRADE OFFICE! He has ZERO rights to any technology related to the patent / intellectual property referred to in the lawsuit.
VDRM will have the right to countersue based on defamation, financial damages and false allegations!!!
$VDRM CHECK THIS OUT! SCREEN SHOTS OF THE PATENTS KEOUGH ABANDONED! Case will be dismissed in my opinion based on my conversations with legal professionals, including a patent attorney.
SCREEN SHOTS DIRECTLY FROM THE US PATENT TRADE OFFICE
$VDRM This Technology and The Company Are As Real as it gets!
The Federal Law will validate everything Dr Otiko has stated, leading to a much higher valuation on the stock in my opinion
Two new items in the May 3rd press release Worth Highlighting!
The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.
The Company is moving ahead with its aggressive growth plans and plans to complete its initial production of Viabecline topical antibiotic by the end of Q2."
ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for MenThe Company's National Drug Code for its Prolayed uses Lidocaine & the Company's Proprietary Topical Solution to Solve Premature Ejaculation for Men Can Now be Sold in Retail Stores
LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation.
The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future.
This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products.
Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period.
Company Update The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.
About ViaDerma, Inc. ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's topical antibiotic uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Prolayed 69006-010-0010 mg/mL Dosage Form OINTMENT Route TOPICAL Appl. No. part 333B Labeler Name ViaDerma, Inc Product NDC 69006-010 Nonproprietary Name LIDOCAINE Substance Name LIDOCAINE Product Type Name HUMAN OTC DRUG
Start Marketing Date 06-23-2017
End Marketing Date N/A
Market Category OTC MONOGRAPH FINAL Package Description 15 mL in 1 BOTTLE (69006-010-00)
Product will begin rolling out in 45 to 60 days. "
$VDRM Viabecline DRUG News LOAD UP BEFORE THIS IS PRESS RELEASED BY THE CO
This Stock Could Go to Dollars In My Opinion!!!
Viabecline has already begun to launch through DRUG retailers. HUGE Sales Coming! Similar PLAY to OWC PHARMA!!
Viabecline is registered with the FDA as first aid to help prevent skin infection in minor cuts, scrapes, and burns.
Evolution is how bacteria develop resistance to the effects of all antibiotics. Papers and articles on antibiotic resistance evolution of bacteria have concentrated almost entirely on CHEMICAL threats to the bacteria. The mechanism of action of all known antibiotics is chemical in nature. Chemical (biochemical) processes previously have been the primary focus when combating bacteria drug resistance. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat. This is why Viabecline is able to kill all bacteria it has been tested on, and is also the reason why antibiotic resistance will be very difficult.
The patent-pending transdermal delivery system allows the active ingredient (tetracycline) to be carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than other antibiotics. Most other antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our product usually produce desirable results in 24 hours (or less).
Viabecline contains Vitamin D3 in the form of cholecalciferol. This is an essential component of skin healing. More benefits of Vitamin D3 can be found in the product benefits section. Viabecline not only helps prevention or treat infection, it also helps heal the skin from damage caused by the infection.
Viabecline contains Vitamin C in the form of ascorbic acid. This is an essential component of skin healing. More benefits of Vitamin D3 can be found in the product benefits section. Viabecline not only helps prevention or treat infection, it also helps heal the skin from damage caused by the infection because it contains Vitamin C and D3.
At Accuria, we like to refer to Viabecline as a “super-drug”. We believe it is one of the world’s strongest topical antibiotics. Viabecline kills all harmful Gram positive and Gram negative bacteria that have been available for testing We have put this amazing antibiotic in the hands of people without the need of a prescription needed. We use both a physical and a chemical mechanism of kill to fight pathogens.
All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of Viabecline’s strength.
PRODUCT INGREDIENTS
Active Ingredient (in each gram): Tetracycline Hydrochloride 30mg
Viabecline contains Vitamin D which has the following benefits for the skin:
Minimize acne, boost elasticity, stimulate collagen production, enhance radiance, lessen lines and the appearance of dark spots. Vitamin D Cream or supplements can be effective for treatment of psoriasis. Vitamin D also repairs skin damage prevents infections that might be caused due to skin injuries and rejuvenate the skin. One of the most well-known uses for Vitamin D in terms of skin is its treatment of psoriasis. Psoriasis symptoms include itchy and flaky skin, which can heal by the topical application of Vitamin D cream or by having prescribed Vitamin D supplements.
Vitamin D3 contains strong anti-inflammatory properties which make it effective for treating burns, skin injuries, skin damage and stretch marks. Thus vitamin D is added to Viabecline for its anti-inflammatory properties.
Vitamin D also helps to treat eczema and is a potential saviour of rosacea sufferers. Enzymes in the skin of rosacea sufferers can cause them to produce antimicrobial peptides in an abnormal form
Viabecline also contains Vitamin C (ascorbic acid). The antioxidant properties of vitamin C and its role in collagen synthesis make vitamin C a vital molecule for skin health. Topical ascorbic acid has the following beneficial effects on skin cells.
Production of Collagen: Vitamin C is a required component for the production of hydroxyproline and hydroxylysine, both of which are needed to bind the molecules that produce collagen. This, in turn, firms and tones the skin. Collagen deficiency makes the skin dull and lifeless. Collagen rejuvenates the skin from the roots and reduces wrinkles and symptoms of aging.
Heals Wounds: The body uses Vitamin C to replace the damaged tissue and helps to heal the wound at a faster pace. Wounds that heal slowly indicate Vitamin C deficiency. Vitamin C improves the skin elasticity and helps to create scar tissue and ligaments for quick recovery.
Protects Against Skin Discoloration: Vitamin C protects DNA from photochemical reactions that can lead to tumor, skin discoloration and several kinds of skin cancer. It also inhibits the production of Pyrimidine dimers that are the primary cause of melanomas in humans.
It lightens dark discoloration like skin freckles and age spots and helps to get a younger and smoother skin.
Improves Skin Texture: Collagen also provides the structure for the blood vessels. The tiny blood vessels under the skin carry oxygen and nutrients that keep the skin healthy. Without enough nutrients, the skin will become rough and dry. Creams containing Vitamin C improve the appearance and texture of the skin.
Vitamin C increases the formation of elastin which thickens, protects and heals the skin cells. The thickening effect helps retain moisture, increases the skin circulation and plumps up the skin surface.
BENEFITS
Infection Protection. It works by killing sensitive bacteria on the skin or in wounds. So far it has killed 99% of all bacteria it has been tested on. Prevention of wound infection following minor surgical or cosmetic procedures. Relieves symptoms associated with secondarily infected eczematous dermatitis. Relieves symptoms associated with secondarily infected acne. Relieves symptoms associated secondarily infected psoriasis. Soothes Painful Cuts, Scrapes, and Burns. Rapid Absorption.
POSSIBLE REACTIONS/COUNTER INDICATORS
Anyone allergic to tetracycline should not use. Do not use if allergic to any ingredient listed on this label.
Warnings For external use use only.
May be harmful is swallowed.
Do not use in eyes.
Do not use longer than 1 week unless directed by doctor.
Ask a doctor before use if you have deep or puncture wounds animal bites serious trauma. Stop use and ask a doctor if condition persists or gets worse.
Keep out of reach of children.
If swallowed, get medical help or contact a Poison control Center right away.
PACKAGING SIZES:5 ml bottle15 ml bottle28 ml spray bottle
OTHER INFORMATION:Keep product refrigerated to preserve its effectiveness and color, stop use if product is misused. This product is an OTC antibiotic for human use. Contains no alcohol, no animal ingredients. Blended for typical skin color. May stain cloth
No claims regarding stem cell healing are implied for this product.
Found an abstract from last year on Dave Pozek of Accuria on linkedin.
VDRM NEW DRUG NEWS / DRUGS LAUNCHING ! NEWS IMMINENT !!
LABELING / PACKAGING DONE!
Viabecline
Dosage form: ointment Ingredients: TETRACYCLINE HYDROCHLORIDE 30mg in 1mL Labeler: VIADERMA II, INC. NDC Code: 69006-002
Viabecline Topical Ointment
Active Ingredient (in each gram)
Tetracycline Hydrochloride 30mg
Purpose
First Aid antibiotic
Use
First aid to help prevent skin infection in minor cuts, scrapes, and burns.
Warnings
For esternam use only. May be harmful is swallowed.
Allergy alert: Do not use if allergic to any ingredient listed on this label.
Do not use
In eyesover large areas of the body longer than 1 week unless directed by doctor
Ask a doctor before use if you have
Deep or puncture wounds animal bitesserious trauma
Stop use and ask a doctor if condition persists or gets worse.
Keep our of reach of children. If swallowed, get medical help or contact a Poison control Center right away.
Directions Clean the affected area Apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily. May be covered with a sterile bandage.
Other Information Keep product refrigerated to preserve its effectiveness and colorStop use if product is misused This product is an OTC antibiotic for human use Contains no alcohol, no animal ingredients Blended for typical skin colorMay stain cloth No claims regarding stem cell healing are implied for this product.
SHORT SELLERS ARE CLEARLY LOSING CONTROL AND THIS IS ON THE VERGE OF EXPLODING HIGHER. FACTS ARE BELOW!
#SHORTSQUEEZE IMMINENT
ALL READ THE FOLLOWING!
<<<<SEE NEW SHORT INTEREST FIGURES BELOW>>>
The SHORT Reports are Reported Directly From Finra!
There's ZERO BS. IT'S FACTS, and extremely telling!
Anyone thinking about selling INTO this RALLY, really needs to think twice!
There's a reason why the PERCENTAGE of Volume SOLD SHORT per day has increased so dramatically!!!
The Short SELLERS got pegged against the wall and are trying to stop the UPWARD MOMENTUM, with there fake walls.
Nobody who's half intelligent would place a large block of shares for sale on the ask. The blocks are put there to place a psychological block, to deter people from buying. When you buy into the block, you put FEAR into the short SELLERS and they quickly pullback from there SHORT Attack!
The higher the price goes, the more they lose control!
As the stock climbs, it gains momentum which will lead to a larger climb, creating a short squeeze and "A PANIC BUYING" SITUATION.
This stock is being artificially held down. The volume is at record lows for four straight business days. The majority of the shares being sold, are from short sellers.
There is practically no more shares available at this level.
So what you see taking place, is trading from one short seller to another.
They artificially dropped the share price down by selling back and forth between there accounts, using the same shares.
THE minute any volume comes in to buy, that is not a short seller, the stock instantaneously rises on the bid and ask at the same time.
Most shareholders are holding, as 90% of the weak hands have sold.
So there continuously shaking the tree by creating artificial volume at a deflated stock price, hoping to create fear. (Based on the volume, they have already lost!)
But what actually has taken place is, the entire floats been locked up by stronger hands, creating added pressure on short SELLERS. (Now they are forced to try and figure out ways to create fear, hence misleading posts, rumors, confusion etc.)
This is a coiled spring and will explode higher in a matter of days just like it has done over and over, during the past 4 months.
Be strong and don't fall for these games! Place a bid in , good til canceled and take away the remainder of the shares from short SELLERS. .
Also confirmed with Management that there will be ZERO DILUTION from today until September 2017. CONFIRMED !
_______________________________________
PER IR " In the last month there were 10 million shares issued as a result of a convertible note. There are no more issuance is expected until another note comes due beginning in either September or October and it will be staggered for a couple months. So no more issuance of shares until the fall"
"To date not one single Insider has sold any shares"
"Dr Otiko owns over 40 million shares and has not SOLD any shares" directly from IR
INVESTOR RELATIONS
RICHARD INZA 1-954-251-0616 or 1-310-734-6111
info@viadermalicensing.com
____________________________________
$VDRM DUE DILIGENCE
The CEO of VDRM was involved with Phillips on inventing a transdermal delivery system that changes drugs into an ointment for better absorption .
Steven Keogh was the patent attorney several years back. The guys trying to say he had rights to the patent. Which is freakin ridiculous. He's known to be a corrupt attorney who trys to steal intellectual property. So he recently filed a suit against VDRM over the patent. It's a Frivolous suit in my view. Hence the reason the stock dipped.
Steven Keogh is a piece of doodoo patent attorney , trying to extort money from company.
It was abandoned which means that it was never issued because he abandoned it before seeing through the entire process.
Once it's abandoned its fair game anybody can claim it.
But either way the patent that we have is different than the abandoned patent.
We're not even fighting over the same technology as far as I am aware.
Dr Christopher Otiko made changes and improved upon the original technology. He greatly advanced it and filed provisional patents for the new technology.
I did verify the original patent (Referenced by Stephen Keough) was abandoned via us patent trade office.
This is FACTUAL, NOT SPECULATION.
HERE IT IS, DIRECTLY FROM THE US PATENT ORGANIZATIONS WEBSITE!
13/729,776 TOPICAL DRUG DELIVERY SYSTEM WITH DUAL CARRIERS Status: Abandoned -- Failure to Respond to an Office Action Status Date: 11-16-2015 First Named Inventor: D. Howard Phillips , Millerton, OK First Named Applicant: PHARMACLINE, LLC , Minneapolis, MN
Patent info from DR Otiko took 20 mins for response...
The original patent filed by Steve Keough was abandoned. Keough the patent attorney for Dr. Phillips who invented the technology with my assistance. I was responsible for 90% of the data that led to the patent, HOWEVER Keough put himself on as an inventor, which wasnt true. The patent was abandoned because Keough and Dr. Phillips had a falling out. I filed a provisional patent to protect the IP. Hope this helps clarify things.
Dr. Chris Ayo Otiko, President & CEO ViaDerma, Inc Corporate Headquarters 4640 Admiralty Way Suite 500, Marina Del Rey, CA 90292 Phone: (310) 496-5744 Fax: (310) 943-1457 viadermalicensing.com/
People are missing this KEY section.
Directly from the Annual Report
"Furthermore, the predecessor transdermal technology, which is the subject of dispute by Mr. Keough, is not even currently used by the Company and any protections related to its provisional patents are believed to have expired. All new products being developed and sold by the Company are based on a newer transdermal technology created directly by the Company or its management team. "
RECENT THIRD PARTY DUE DILIGENCE
$VDRM Here's Something Viaderma Inc $VDRM Shareholders Should See
By Chris Sandburg / in Biotech, Momentum & Growth, Momentum Stocks, Stocks / on Wednesday, 10 May 2017 10:58 AM / 0
Viaderma Inc (OTCMKTS:VDRM) took a bit of a hit recently based on the surfacing of some litigation related to the delivery method associated with its lead asset. Over the last few days, however, the company has recovered much of the lost ground, trading up to the tune of around 20% on the Monday open at current prices (midsession on Wednesday) and up close to 10% for the day so far.
With the potential for an FDA green light for its lead registration asset just around the corner, and the company fresh off the back of what was reported as being a successful conference presentation by its CEO relating to the lead target indication – diabetic foot ulcer therapy – it looks as though we could be in for some strength. The litigation dampens sentiment somewhat, however, right now, but a little bit of digging reveals that sentiment need not be impeded by what’s going on.
Here is why.
By way of a bit of background, Viaderma has developed a topical antibacterial formulation of an already FDA registered drug, which it has been able to prove in trials has the potential to treat diabetic foot ulcers successfully in more than 90% of applications. This category of condition is crying out for fresh therapy options right now, and a number of companies have failed in their attempts to bring said options to market just recently. We covered this company not long ago, requesting that management put out some degree of insight (by way of a press release or otherwise) as to how the above-mentioned presentation went. To put it bluntly, we felt that the claims made as to the 90% success rate in this indication were too good to be true, and wanted to see how the scientific community responded to said claims.
Shortly after our coverage, we got exactly what were looking for, with this release.
The product is in final testing for manufacturing, and based on the available evidence, should be a shoo-in for a quick transition toward standard of care therapy in this sector. So what’s holding the company back? Well, as mentioned, there is a claim against the technology that underpins the product.
Specifically, one of the guys who worked on a product (a patent lawyer) with the current CEO and the technology’s initial inventor (a scientist) claims to have ownership rights. If this is the case, it’s potentially terminal for the program. However, it doesn’t take too much digging to prove that the claim is essentially baseless.
Head over to this site.
Insert the following into the field as an application number: 13/729776.
This is the application number for the patent that the guy we’re talking about is trying to challenge – his name is Steven Keough and he’s listed as an inventor on the patent, along with D. Howard Phillips.
Check the status of the patent:
” Abandoned — Failure to Respond to an Office Action”
So first of all, the patent isn’t even a patent – it’s an application.
More important that that, however, it has been abandoned. When a patent application gets abandoned it’s as if nothing has ever been filed. Even if an individual is listed as an inventor on the application, his or her rights to any return based on future commercial application of the technology covered by the initial application are non-existent.
This is all based on a bit of research in a murky area – we aren’t patent lawyers and we don’t work at the USPTO. We may be misinterpreting something (although we’re pretty certain we aren’t), so we’re going to say that it’s important for anyone thinking about acting on our coverage to do a bit of due diligence before doing so.
All said, however, this just looks like a bit of opportunism from Keough.
If that’s the case, then, our bull thesis remains firm, and our attention returns to the science (and the therapeutic application) as near term value inputs.
We will be updating our subscribers as soon as we know more. For the latest updates on VDRM, sign up below!
Sign up for next microcap runner ahead of the crowd.
I bought. If the lawsuit gets dismissed it will skyrocket in my opinion as the lawsuit basically VALIDATES there's significant value on the patent not currently priced in!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AI
